Neuroplast reports successful Phase 1 trial for chronic spinal cord injury stem cell treatment

Dutch biotech company, Neuroplast, announced positive clinical Phase I results after analysis of ten patients suffering from traumatic spinal cord injury (TSCI), with data demonstrating that its investigational stem cell treatment, Neuro-Cells, appears to be safe and well tolerated, without product-related adverse events. The treatment uses the patient’s own stem cells to prevent further loss of function after sustaining TSCI, in an effort to limit loss of mobility and independence of otherwise life-long impairment.

The Phase I study evaluated the safety and tolerability of the Neuro-Cells stem cell preparation for intrathecal application (injection into the spinal canal). Ten patients with SCI, who sustained the trauma between one and five years ago and suffered either an incomplete or a complete lesion, received the Neuro-Cells treatment, manufactured from the patient’s own bone marrow.

You can read more about this study HERE.